NCT02595970 - Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

May 20, 2015

Primary Completion Date

February 9, 2017

Study Completion Date

February 9, 2017

Conditions

Psoriasis

Interventions

DRUG

Secukinumab

weekly sub cutaneous injections of 300 mg during the first month and then monthly until week 52 plus extension until 03/11/2016.

Trial Locations (17)

13500

Novartis Investigative Site, Martigues

13885

Novartis Investigative Site, Marseille

17019

Novartis Investigative Site, La Rochelle

29609

Novartis Investigative Site, Brest

31400

Novartis Investigative Site, Toulouse

33076

Novartis Investigative Site, Bordeaux

57077

Novartis Investigative Site, Metz

72037

Novartis Investigative Site, Le Mans

75014

Novartis Investigative Site, Paris

75877

Novartis Investigative Site, Paris

76031

Novartis Investigative Site, Rouen

80054

Novartis Investigative Site, Amiens

83800

Novartis Investigative Site, Toulon

87000

Novartis Investigative Site, Limoges

92160

Novartis Investigative Site, Antony

95107

Novartis Investigative Site, Argenteuil

06202

Novartis Investigative Site, Nice